Form 4: aTyr Pharma Director Jane A. Gross Acquires 50,000 Stock Options

Director Jane A. Gross acquired 50,000 stock options in aTyr Pharma Inc. on May 1, 2025, according to a Form 4 filing.

Summary

• On May 1, 2025, Jane A. Gross, a director of aTyr Pharma Inc., was granted 50,000 stock options.
• The exercise price of these options is $3.34.
• The options vest fully on the earlier of May 1, 2026, or the Issuer's 2026 Annual Meeting of Stockholders, contingent upon continued service on the Board of Directors.
• The options expire on May 1, 2035.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine disclosure of stock option grants to a company director. It suggests alignment of interests but doesn't inherently indicate positive or negative performance.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership of securities. It is common for directors and officers of publicly traded companies to receive stock options as part of their compensation.

Stakeholder Impact

• The granting of stock options to a director aligns their interests with those of the shareholders, potentially incentivizing them to work towards increasing shareholder value.

Key Dates

Keywords

aTyr Pharma, Stock Options, Form 4, Director, Beneficial Ownership, Jane A. Gross